Standardized 18F-FDG PET/CT in patients with myeloma: joint recommendation of Czech Myeloma Group and Czech Society of Nuclear Medicine

Czech version

Authors: M. Havel ^1*; T. Jelínek ^2,3*; L. Pour ³; M. Štork ³; J. Minařík ⁴; A. Jungová ⁵; I. Špička ⁶; P. Pavlíček ⁷; J. Radocha ⁸; V. Maisnar ⁸; M. Wróbel ⁹; M. Sýkora ¹⁰; J. Ullrychová ¹¹; L. Muroňová ²; E. Krčálová ¹²; E. Buriánková ¹³; L. Henzlová ¹³; G. Havlová ¹; D. Zogala ¹⁴; R. Hájek ²
Authors‘ workplace: Klinika nukleární medicíny, FN Ostrava a LF OU ¹; Klinika hematoonkologie, FN Ostrava a LF OU ²; Interní, hematologická a onkologická klinika LF MU a FN Brno ³; Hemato-onkologická klinika LF UP a FN Olomouc ⁴; Hematologicko-onkologické oddělení, FN Plzeň ⁵; I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze ⁶; Hematologická klinika 3. LF UK a FN Královské Vinohrady ⁷; IV. Interní hematologická klinika LF UK a FN, Hradec Králové ⁸; Hematologické oddělení, Onkologické centrum Nový Jičín ⁹; Oddělení klinické hematologie, Nemocnice České Budějovice ¹⁰; Oddělení klinické hematologie, Masarykova nemocnice Ústí nad Labem ¹¹; Oddělení nukleární medicíny LF UK a FN Hradec Králové ¹²; Klinika nukleární medicíny LF UP a FN Olomouc ¹³; Ústav nukleární medicíny, VFN v Praze ¹⁴
Published in: NuklMed 2023;12:22-26
Category:

Overview

Multiple myeloma is a blood cancer characterized by proliferation of clonal plasma cells in the bone marrow and the presence of paraprotein in the serum and/or urine. In recent years, whole-body positron emission tomography (PET) imaging combined with computed tomography (PET/CT) has become a preferred imaging technique for diagnosis and treatment. It has the benefit of detecting metabolically active characteristic focuses and good detection of extramedullary and paramedullary lesions. The following text presents the collective opinion of the representatives of the Czech Society of Nuclear Medicine ČLS JEP z.s. (CSNM ČLS JEP) and the Czech Myeloma Group (CMG) on PET/CT as well as on its evaluation and reporting. The aim is to standardize the methodology of PET/CT examination across the Czech Republic, which will be clear and simple to understand.

Keywords:

Multiple myeloma – evaluation of treatment response – complete metabolic response – extramedullary lesions – 18F-FDG PET/CT – paramedullary lesions

Sources

Moulopoulos LA, Koutoulidis V, Hillengass J, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer Journal. 2018;8(10):95
Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. The Lancet Oncology. 2017;18(4):e206-e217
Kumar S, Glazebrook KN, Broski SM. Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma. PET Clinics. 2019;14(3):391-403
Nanni C, Zamagni E. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma. PET Clinics. 2019;14(3):383-389
Seval GC, Ozkan E, Beksac M. PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma. PET Clinics. 2019;14(3):369-381
Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-55
Muronova L, Havel M, Popkova T, et al. Prognostic Value of PET/CT Performed Day +100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience. Blood. 2020;136(Supplement 1):6-7
Sevcikova S, Minarik J, Stork M, et al. Extramedullary disease in multiple myeloma – controversies and future directions. Blood Reviews. 2019;36:32-39
Jelinek T, Zihala D, Sevcikova T, et al. Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets. Blood. 2021;138(Supplement 1):2680-2680
Jelinek T, Sevcikova T, Zihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36(1):288-291
Standardy zdravotní péče - „Národní radiologické standardy - nukleární medicína“. Soubor doporučení a návod pro tvorbu místních radiologických postupů (standardů) na diagnostických a terapeutických pracovištích nukleární medicíny v České republice. Věstník Ministerstva zdravotnictví České republiky. 2016;2016(2/2016):203-364
Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42(2):328-354
Zamagni E, Nanni C, Dozza L, et al. Standardization of 18 F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 2021;39(2):116-125
Adam Z, Bolcak K, Stanicek J, et al. Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance. Neoplasma. 2007;54(6):536-540
Jelinek T, Bezdekova R, Zihala D, et al. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma. JCO. 2023;41(7):1383-1392
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology. 2016;17(8):e328-e346

Labels

Nuclear medicine Radiodiagnostics Radiotherapy

Editorial

Stereotactic radiotherapy with CyberKnife added to local therapy of differentiated thyroid cancer

Primary DLBCL lymphoma in sacral bone – case report

Nuclear Boot Camp, Zubří, 12. – 14. 5. 2023

11. Konference radiologické fyziky, Ostrava, 19. – 21. 4. 2023

26. pracovní den technologicko-ošetřovatelské sekce ČSNM, Praha

Historický kvíz

Sonda do historie

Article was published in

Nuclear Medicine

2023 Issue 2